Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michael Y Shapira, Igor B Resnick, Panagiotis D Tsirigotis & Shimon Slavin. (2006) Biological response modifiers as adjuncts to stem cell transplantation. Expert Opinion on Biological Therapy 6:5, pages 467-483.
Read now
Read now
Bryon D. Johnson, Carrie A. Hanke & Robert L. Truitt. (1996) The Graft-Versus-Leukemia Effect of Post-transplant Donor Leukocyte Infusion. Leukemia & Lymphoma 23:1-2, pages 1-9.
Read now
Read now
Articles from other publishers (46)
Shimon Slavin. (2023) Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte. Journal of Cancer Research and Clinical Oncology 149:11, pages 9277-9284.
Crossref
Crossref
Scott S Graves, Maura H Parker & Rainer Storb. (2018) Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. ILAR Journal 59:3, pages 263-275.
Crossref
Crossref
Mi-Sun Choi, Ji-Young Lim, Byung-Sik Cho, Yoo-Jin Kim, Nack-Gyun Chung, Dae Chul Jeong, Hyewon Youn, Chulbom Lee, Eun Young Choi & Chang-Ki Min. (2011) The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice. Leukemia Research 35:12, pages 1549-1556.
Crossref
Crossref
Shimon Slavin, Aliza Ackerstein, Reuven Or, Michael Y. Shapira, Benjamin Gesundheit, Nadir Askenasy & Shoshana Morecki. (2010) Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunology, Immunotherapy 59:10, pages 1511-1519.
Crossref
Crossref
Edwin P. Alyea. (2008) Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect. Best Practice & Research Clinical Haematology 21:2, pages 239-250.
Crossref
Crossref
Ji-Young LimBo-Gyeong KimSeol-Kyung MoonChang-Ki Min. (2008) Enhancement of Graft-versus-leukemia Effects by Mesenchymal Stem Cells in Mixed Chimerisim after a Murine Non-myeloablative Hematopoietic Stem Cell Transplantation. The Korean Journal of Hematology 43:4, pages 219.
Crossref
Crossref
Fariba EsmaeiliTaki TiraihiMansoureh MovahedinSeyed Javad Mowla. (2006) Selegiline Induces Neuronal Phenotype and Neurotrophins Expression in Embryonic Stem Cells. Rejuvenation Research 9:4, pages 475-484.
Crossref
Crossref
Iris Yung, Lola Weiss, Ali Abdul-Hai, Judith Kasir, Shoshana Reich & Shimon Slavin. (2005) Induction of Early Post-Transplant Graft-versus-Leukemia Effects Using Intentionally Mismatched Donor Lymphocytes and Elimination of Alloantigen-Primed Donor Lymphocytes for Prevention of Graft-versus-Host Disease. Cancer Research 65:21, pages 9735-9740.
Crossref
Crossref
Shimon Slavin. (2005) Allogeneic Cell-Mediated Immunotherapy at the Stage of Minimal Residual Disease following High-Dose Chemotherapy Supported by Autologous Stem Cell Transplantation. Acta Haematologica 114:4, pages 214-220.
Crossref
Crossref
L Weiss, S Reich, O Mandelboim & S Slavin. (2004) Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. Bone Marrow Transplantation 33:11, pages 1137-1141.
Crossref
Crossref
Shimon Slavin, Shoshana Morecki, Lola Weiss, Michael Y Shapira, Igor Resnick & Reuven Or. (2004) Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy—from bench to patient bedside. Seminars in Oncology 31:1, pages 4-21.
Crossref
Crossref
Beverly A. Teicher. 2004. Anticancer Drug Development Guide. Anticancer Drug Development Guide
243
258
.
Shimon Slavin. (2018) Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation. International Journal of Hematology 78:3, pages 195-207.
Crossref
Crossref
M Y Shapira, R Or, I B Resnick, M Bitan, A Ackerstein, S Samuel, S Elad, I Zilberman, S Miron & S Slavin. (2003) A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 32:6, pages 557-561.
Crossref
Crossref
Shimon Slavin, Shoshana Morecki, Lola Weiss & Reuven Or. (2003) Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Critical Reviews in Oncology/Hematology 46:2, pages 139-163.
Crossref
Crossref
Igor Espinoza-Delgado & Dan L. Longo. 2003. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
83
99
.
Shimon SlavinShoshana MoreckiLola WeissReuven Or. (2002) Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction with Allogeneic Stem Cell Transplantation. Journal of Hematotherapy & Stem Cell Research 11:2, pages 265-276.
Crossref
Crossref
I. Nir, L. Weiss & S. Slavin. 2002. Melatonin After Four Decades. Melatonin After Four Decades
407
409
.
C Ferrá, M Rodríguez-Luaces, D Gallardo, M Encuentra, GA Martín-Henao, J Peris, I Ancín, J Sarrá, JJ Berlanga, J García & A Grañena. (2001) Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation 28:10, pages 963-968.
Crossref
Crossref
Shimon Slavin. (2001) Immunotherapy of cancer with alloreactive lymphocytes. The Lancet Oncology 2:8, pages 491-498.
Crossref
Crossref
Shimon Slavin, Arnon Nagler, Michael Shapira, Soumya Panigrahi, Simcha Samuel & Arnon Or. (2001) Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Critical Reviews in Oncology/Hematology 39:1-2, pages 25-29.
Crossref
Crossref
Shoshana Morecki, Elena Yacovlev, Yael Gelfand, Ifat Uzi & Shimon Slavin. (2001) Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma. Journal of Immunotherapy 24:2, pages 114-121.
Crossref
Crossref
Arnon Nagler, Aliza Ackerstein, Reuven Or, Elizabeth Naparstek & Shimon Slavin. (2000) Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Experimental Hematology 28:11, pages 1225-1231.
Crossref
Crossref
Shimon Slavin. (2000) New strategies for bone marrow transplantation. Current Opinion in Immunology 12:5, pages 542-551.
Crossref
Crossref
H. Sefrioui, A. D. Billiau & M. Waer. (2000) GRAFT-VERSUS-LEUKEMIA EFFECT IN MINOR ANTIGEN MISMATCHED CHIMERAS GIVEN DELAYED DONOR LEUCOCYTE INFUSION: IMMUNOREGULATORY ASPECTS AND ROLE OF DONOR T AND ASGM1-POSITIVE CELLS1. Transplantation 70:2, pages 348-353.
Crossref
Crossref
Stephen Mackinnon. (2000) Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?. British Journal of Haematology 110:1, pages 12-17.
Crossref
Crossref
Shoshana MoreckiShimon Slavin. (2000) Toward Amplification of a Graft-Versus-Leukemia Effect While Minimizing Graft-Versus-Host Disease. Journal of Hematotherapy & Stem Cell Research 9:3, pages 355-366.
Crossref
Crossref
John BarrettShoshana Morecki, Gabor Varadi, Elizabeth Naparstek, Rami Ben-Yosef, Shimon Slavin, Arnon Nagler & Reuven Or. 2000. Allogeneic Immunotherapy for Malignant Diseases. Allogeneic Immunotherapy for Malignant Diseases.
Shimon Slavin & Arnon Nagler. 2000. Cancer and Autoimmunity. Cancer and Autoimmunity
409
421
.
S. Slavin, A. Nagler, E. Naparstek, G. Varadi, R. Ben-Yosef & R. Or. 2000. Transplantation in Hematology and Oncology. Transplantation in Hematology and Oncology
112
117
.
Urania Vourka-Karussis, Aliza Ackerstein, Thea Pugatsch & Shimon Slavin. (1999) Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease. Experimental Hematology 27:3, pages 461-469.
Crossref
Crossref
David L. Porter & Joseph H. Antin. (1998) INFUSION OF DONOR PERIPHERAL BLOOD MONONUCLEAR CELLS TO TREAT RELAPSE AFTER TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA. Hematology/Oncology Clinics of North America 12:1, pages 123-150.
Crossref
Crossref
S. Slavin & A. Nagler. (1998) Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Annals of Oncology 9, pages S31-S39.
Crossref
Crossref
A. NaglerA. AckersteinR. OrE. NaparstekS. Slavin. (1997) Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-α in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation. Blood 89:11, pages 3951-3959.
Crossref
Crossref
Stephen Mackinnon. (1997) 11 Donor leukocyte infusions. Bailli?re's Clinical Haematology 10:2, pages 357-367.
Crossref
Crossref
Beverly A. Teicher. 1997. Anticancer Drug Development Guide. Anticancer Drug Development Guide
183
196
.
David L. Porter & Joseph H. Antin. 1997. Blood Stem Cell Transplantation. Blood Stem Cell Transplantation
57
85
.
A.R. Perry & S. Mackinnon. (1996) Adoptive immunotherapy post bone-marrow transplantation. Blood Reviews 10:4, pages 237-241.
Crossref
Crossref
Robin Foa, Alessandro Cignetti & Anna Guarini. (2012) Acute Leukaemia. Clinical Immunotherapeutics 6:3, pages 238-249.
Crossref
Crossref
Amos Toren, Aliza Ackerstein, Shimon Slavin & Arnon Nagler. (1995) Role of interleukin-2 in human hematological malignancies. Medical Oncology 12:3, pages 177-186.
Crossref
Crossref
J. Nemunaitis, C. Rosenfeld, R. Collins, P. Pallansch, L. Pineiro, S. Ohr, D. Waxman, M. Stone, J. Fay, W. Miller & Luis Piñeiro. (2003) Allogeneic transplantation combining mobilized blood and bone marrow in patients with refractory hematologic malignancies. Transfusion 35:8, pages 666-673.
Crossref
Crossref
E. Naparstek, R. Or, A. Nagler, G. Cividalli, D. Engelhard, M. Aker, Z. Gimon, N. Manny, T. Sacks, Z. Tochner, L. Weiss, S. Samuel, C. Brautbar, G. Hale, H. Waldmann, S. M. Steinberg & S. SLAVIN. (2008) T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. British Journal of Haematology 89:3, pages 506-515.
Crossref
Crossref
Esperanza B. Papadopoulos, Marc Ladanyi, David Emanuel, Stephen Mackinnon, Farid Boulad, Matthew H. Carabasi, Hugo Castro-Malaspina, Barrett H. Childs, Alfred P. Gillio, Trudy N. Small, James W. Young, Nancy A. Kernan & Richard J. O'Reilly. (1994) Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine 330:17, pages 1185-1191.
Crossref
Crossref
GEOFF HALE & HERMAN WALDMANN. (1994) CAMPATH-1 Monoclonal Antibodies in Bone Marrow Transplantation. Journal of Hematotherapy 3:1, pages 15-31.
Crossref
Crossref
Pierre Tiberghien & Patrick Hervé. (1992) Perspectives in marrow graft T-cell depletion in allogeneic matched related bone marrow transplantation. Transfusion Science 13:4, pages 443-454.
Crossref
Crossref
Simcha Samuel, Arnon Nagler, Reuven Or & Shimon Slavin. (1992) Effects of interleukin 2 on engraftment following autologous bone marrow transplantation (ABMT) in dogs. Leukemia Research 16:10, pages 967-972.
Crossref
Crossref